Gaviscon firm Reckitt Benckiser agrees £10.2m fine
Reckitt Benckiser has been fined more than £10m for abusing its market position in the supply of heartburn medicine.
The firm has been accused by the Office of Fair Trading of rigging the market for the heartburn drug Gaviscon. The OFT says the firm tried to restrict competition by only offering NHS doctors a more expensive version of their product rather than allowing them to opt for a cheaper generic one.
Ann Pope is the OFT's senior director for goods and she explained why the fine was reduced from £12m to £10.2m.
15 Oct 2010
- From the section Business